Clinical Trial

Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high risk for gastric cancer. Moreover, the implementation of eradication interventions in high-risk groups has the potential to significantly reduce the incidence and progression of gastric cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-22; most recent amendment 2026-02-23.
Trial Details
NCT Number NCT06943794
Lead Sponsor Fudan University
Conditions Gastric (Stomach) Cancer
Enrollment 4,824 participants
Start Date 2026-03-30
Primary Completion 2030-05-01 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-25